Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

108.90EUR
11:35am EDT
Change (% chg)

€2.50 (+2.35%)
Prev Close
€106.40
Open
€107.20
Day's High
€109.25
Day's Low
€106.85
Volume
1,766,494
Avg. Vol
2,023,604
52-wk High
€123.90
52-wk Low
€86.03

Latest Key Developments (Source: Significant Developments)

Dow Chemical updates on patent dispute with Bayer
Thursday, 9 Feb 2017 09:38am EST 

Dow Chemical Co : Dow Chemical - In January 2017, the USPTO issued final office actions for two of the patents asserted in a case, including the ‘962 patent . Dow Chemical - USPTO rejected all relevant claims related to a patents dispute with Bayer, based on the doctrine against double-patenting . Dow Chemical - Re-examination proceedings with respect to other two patents remain pending, although co anticipates that USPTO will likewise invalidate those patents . Dow Chemical - Although Bayer may appeal these decisions, co believes USPTO final office actions will provide a strong basis to vacate the arbitral award .Dow Chemical - As part of the co’s review of the arbitral award, co assessed the legal and factual circumstances of the case.  Full Article

Regeneron says price increases unrelated from innovation will be pushed back on
Thursday, 9 Feb 2017 09:00am EST 

Regeneron Pharmaceuticals Inc - : Regeneron CEO: "As we further diversify our product related revenue stream, we do not plan to provide eylea guidance after 2017" . Regeneron CEO says Amgen's asserted patent claims on repatha are invalid and we look forward to pursuing our appeal over the coming months: conf call . Regeneron's Bob Terifay says Eylea will continue for co over the years to come . Regeneron: Eylea sales growth has slowed reflecting normal market dynamics for the product that has been around for over 5 yrs with no price hike since launch . Regeneron CEO says changes in pharmaceutical drug pricing will need congressional action . Regeneron CEO "Price increases that are unrelated or uncoupled from innovation will be pushed back on" . Regeneron CEO: Constant price increases & magnitude of them are reflection of tone deafness on those taking hikes & complexities about how rebates work . Regeneron CEO: "There is an opportunity to come up with more responsible pricing", in relation to rheumatoid arthritis drug, sarilumab . Regeneron CEO: "Pharma is running around saying the middleman (PBM) is taking too much; the middleman says prices are too high and patients are wondering what is really going on" . Regeneron CEO: "price increases are nice but if you cannot get them you better be able to innovate and that is our sweet spot" Further company coverage: [AMGN.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Bayer says Regorafenib granted priority review in Japan
Friday, 20 Jan 2017 02:02am EST 

Bayer AG : Bayer says Regorafenib from Bayer granted priority review in Japan for the second-line treatment of liver cancer Further company coverage: [BAYGn.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

Bayer, Leica Biosystems to develop companion diagnostic test for cancer patients
Wednesday, 21 Dec 2016 02:38am EST 

Bayer AG : Says develops companion diagnostic test for cancer patients together with Leica Biosystems . The partners will use Leica Biosystems expertise in assay development, regulatory approval and commercialization of companion diagnostic tests .Financial terms of the agreement were not disclosed.  Full Article

Bayer announces FDA acceptance of supplemental biologics license application for Mybetaapp and Betaconnect navigator
Wednesday, 14 Dec 2016 12:18pm EST 

Bayer:Bayer announces fda acceptance of supplemental biologics license application for mybetaapp and betaconnect navigator.  Full Article

Bayer buys U.S. animal health products from Boehringer
Wednesday, 7 Dec 2016 11:05am EST 

Bayer AG : Says Boehringer Ingelheim Vetmedica, Inc. and Bayer enter into agreement for purchase of U.S. Cydectin® product portfolio . Says to acquire Boehringer's Cydectin bovine and ovine endectocide products in United States .Says the sale of Boehringer's U.S. Cydectin products is a required step toward its acquisition of Merial as part of a swap transaction with Sanofi.  Full Article

Monsanto provides update on Bayer merger
Tuesday, 22 Nov 2016 06:04am EST 

Bayer Ag : Monsanto co - in connection with merger with Bayer, a purported class action lawsuit, captioned ken gawrych, was filed on nov. 16, 2016 . Monsanto- complaint asserts board breached fiduciary duties by agreeing to deal not adequately reflecting co's true value to obtain personal benefits .Monsanto- complaint seeks to enjoin the consummation of the merger; monsanto believes the claims asserted in lawsuit are without merit.  Full Article

Germany's Bayer mandatory convertible bond issue covered - source
Tuesday, 15 Nov 2016 01:26pm EST 

Germany's Bayer : 4 billion euro mandatory convertible bond issue covered - source (Reporting by Dasha Afanasieva).  Full Article

Bayer CEO makes case for U.S.-EU trade after Trump win
Wednesday, 9 Nov 2016 08:02am EST 

Bayer Chief Executive Werner Baumann, commenting on Donald Trump's U.S. presidential election victory:. "After an intense election campaign, the new U.S. president is facing important challenges. For example, it is now important to further strengthen the partnership between the U.S. and the EU. The expansion of our trade relations is of crucial importance for prosperity on both sides of the Atlantic." .. "Another focus should be to develop the healthcare system in the U.S. in a way that gives more patients access to new and innovative therapies." .. The German drugs and chemicals group has global interests, including a big U.S. business, and has agreed to buy U.S. seeds company Monsanto for $66 billion. [nL8N1BQ365] (Reporting by Ben Hirschler; Editing by Adrian Croft) ((ben.hirschler@thomsonreuters.com; +44 20 7542 5082; Reuters Messaging: ben.hirschler.thomsonreuters.com@reuters.net)) Keywords: USA ELECTION/BAYER.  Full Article

FDA concludes Xarelto clinical trial results not affected by Alere's INRatio
Tuesday, 11 Oct 2016 12:41pm EDT 

U.S. FDA: Analyses conclude that Xarelto clinical trial results were not affected by Alere's faulty monitoring device INRatio .FDA concludes blood thinner drug Xarelto is a safe and effective alternative to warfarin in patients with atrial fibrillation.  Full Article

EU mergers and takeovers (Aug 22)

BRUSSELS, Aug 22 The following are mergers under review by the European Commission and a brief guide to the EU merger process: